Genocea Biosciences Inc (NASDAQ:GNCA) saw a large growth in short interest during the month of September. As of September 14th, there was short interest totalling 2,417,448 shares, a growth of 33.3% from the August 31st total of 1,813,657 shares. Based on an average daily trading volume, of 301,521 shares, the short-interest ratio is presently 8.0 days. Currently, 4.9% of the company’s stock are sold short.
Shares of GNCA stock remained flat at $$0.77 on Friday. The stock had a trading volume of 159,560 shares, compared to its average volume of 774,975. The stock has a market cap of $67.54 million, a P/E ratio of -0.39 and a beta of 0.99. Genocea Biosciences has a 52-week low of $0.49 and a 52-week high of $1.69. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.95.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. Sell-side analysts expect that Genocea Biosciences will post -0.47 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Genocea Biosciences by 169.1% during the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after acquiring an additional 2,488,540 shares during the period. Millennium Management LLC bought a new stake in Genocea Biosciences during the second quarter valued at about $730,000. Northern Trust Corp raised its holdings in Genocea Biosciences by 164.5% during the first quarter. Northern Trust Corp now owns 792,677 shares of the biotechnology company’s stock valued at $833,000 after acquiring an additional 492,961 shares during the period. Paloma Partners Management Co bought a new stake in Genocea Biosciences during the second quarter valued at about $343,000. Finally, DRW Securities LLC bought a new stake in Genocea Biosciences during the second quarter valued at about $205,000. 60.23% of the stock is currently owned by institutional investors.
Several analysts recently weighed in on the company. Zacks Investment Research downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the company a “buy” rating in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Genocea Biosciences has a consensus rating of “Buy” and an average target price of $3.79.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
See Also: Intrinsic Value
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.